Mesoblast (NASDAQ:MESO) Shares Gap Down – Here’s Why

Shares of Mesoblast Limited (NASDAQ:MESO) gapped down prior to trading on Friday . The stock had previously closed at $20.61, but opened at $20.10. Mesoblast shares last traded at $20.35, with a volume of 22,431 shares changing hands.

Analysts Set New Price Targets

A number of analysts recently weighed in on MESO shares. Maxim Group upgraded shares of Mesoblast from a “hold” rating to a “buy” rating and set a $12.00 price target for the company in a research note on Tuesday, September 24th. Jefferies Financial Group lowered Mesoblast from a “buy” rating to a “hold” rating in a report on Monday, December 23rd. Finally, Piper Sandler increased their price objective on Mesoblast from $11.00 to $15.00 and gave the stock an “overweight” rating in a research report on Thursday, December 19th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, Mesoblast presently has an average rating of “Hold” and an average target price of $13.50.

Mesoblast Trading Down 1.2 %

The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.21. The business’s 50 day moving average price is $12.12 and its 200-day moving average price is $9.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. GAMMA Investing LLC boosted its position in shares of Mesoblast by 22.1% during the 4th quarter. GAMMA Investing LLC now owns 6,711 shares of the company’s stock worth $133,000 after purchasing an additional 1,213 shares in the last quarter. Jane Street Group LLC boosted its holdings in Mesoblast by 46.4% during the third quarter. Jane Street Group LLC now owns 85,102 shares of the company’s stock worth $695,000 after buying an additional 26,959 shares in the last quarter. XY Capital Ltd purchased a new stake in Mesoblast during the third quarter worth about $244,000. Signaturefd LLC grew its position in Mesoblast by 128.7% during the third quarter. Signaturefd LLC now owns 5,506 shares of the company’s stock worth $45,000 after buying an additional 3,099 shares during the period. Finally, Creative Planning acquired a new stake in shares of Mesoblast during the 3rd quarter valued at approximately $147,000. Institutional investors and hedge funds own 1.43% of the company’s stock.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.